mPEG-PLGA from PolySciTech used in development of oral delivery of insulin

 

Insulin is an important drug molecule in diabetes management, however its oral delivery is limited. Researchers at The University of Queensland and Hainan Beautech Stem Cell Anti-Aging Hospital used mPEG-PLGA (cat# AK026) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) in development of nanoparticles for oral delivery of insulin. This research holds promise to improve diabetes treatment in the future. Read more: Pang, Huiwen, Wenxuan Yu, Youzhi Wu, Xuqiang Nie, Guojun Huang, Zhi Ping Xu, Chen Chen, and Felicity Y. Han. "Enhanced Epithelial Cell Uptake of Glycol Chitosan‐Coated PLGA Nanoparticles for Oral Drug Delivery." Advanced Therapeutics (2025): 2400547. https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/adtp.202400547

“It is reported that poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) coated with chitosan and its derivatives, such as glycol chitosan (GC), can enhance the targeted uptake of PLGA NPs by intestinal epithelial cells. However, the optimal amount of GC for coating and the specific mechanisms by which it facilitates PLGA endocytosis remain unclear. In this study, PLGA-NPs are prepared using either single- or double-emulsion methods and coated with varying amounts of GC. The results confirmed that GC-coated PLGA NPs are internalized via both clathrin-mediated and caveolae-mediated endocytosis, whereas uncoated NPs relied on only clathrin-mediated endocytosis in Caco-2 and HT-29 cells. The optimized GC-coated PLGA-NPs formulation is further modified by layering alginate to enhance the oral delivery of insulin. In subsequent in vivo studies, the GC and alginate-coated PLGA NPs demonstrated stability and prolonged efficacy, achieving approximately a 50% reduction in blood glucose levels at 6 h post-administration in streptozotocin-induced diabetic mice. These findings provide compelling evidence of the optimal coating amount and molecular mechanisms for GC in the PLGA oral platform, underscoring the feasibility and commercial potential of oral delivery platform based on the optimized GC- and alginate-coated PLGA NPs.”

PLGA (Cat# AK026): https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK026#h

Akina, Inc. launches new GMP manufacturing service available to outside customers https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/